Morgan Stanley Inventiva S.A. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IVA
# of Institutions
8Shares Held
4.85MCall Options Held
0Put Options Held
0-
Yiheng Capital Management, L.P. San Francisco, CA2.64MShares$7.04 Million0.25% of portfolio
-
Nea Management Company, LLC Timonium, MD1.46MShares$3.89 Million0.21% of portfolio
-
Bvf Inc San Francisco, CA686KShares$1.82 Million0.04% of portfolio
-
Commonwealth Equity Services, LLC39.7KShares$105,6950.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA16.3KShares$43,4290.0% of portfolio
About Inventiva S.A.
- Ticker IVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,134,200
- Market Cap $112M
- Description
- Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...